AI assistant
Sending…
Ascelia Pharma — Major Shareholding Notification 2024
Jul 22, 2024
3132_iss_2024-07-22_a34098da-49d5-45c0-90ea-8e437d346adf.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer Ascelia Pharma AB
Holder
Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension
| Aktier |
|---|
| Data not given* |
| Data not given* |
Reason for major shareholding notification Sell Date 19/07/2024 Limit for number of shares 5 %
After the transaction
| Quantity | |
|---|---|
| Shares | 1,718,412 |
| Directly held voting rights | 0 |
| Indirectly held voting rights | 1,718,412 |
| Percentage | |
| Directly held shares | 4.92789 % |
| Directly held voting rights | 0 % |
| Indirectly held voting rights | 5.07369 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 5.07369 % | 1,718,412 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 |
||
| Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled - Cash settled |
0.03498 % | 11,848 |
| Total | 5.10867 % | 1,730,260 |
Group total holdings
Voting rights 1,730,260
Percentage of voting rights 5.10867
Notes (other relevant informations according to law)
Aktierna, samt övriga instrument enligt LHF 4 kap, 2§ första stycket 1 och finansiella instrument enligt LHF 4 kap. 2§ första stycket 3 innehas av Försäkringsaktiebolaget Avanza Pension som är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Det är försäkringskunder som via depåfullmakt har avyttrat de aktuella aktierna.
Published
22/07/2024 10:13
Contact
- Name Marie Karlsfeldt
- Email [email protected]
*Source of information has chosen not to submit the data
CLOSE PRINT
[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Ascelia Pharma
Interim / Quarterly Report
2026
May 12
Interim / Quarterly Report
2026
May 12
AGM Information
2026
May 4
AGM Information
2026
May 4
Share Issue/Capital Change
2026
Apr 30
Share Issue/Capital Change
2026
Apr 30
Share Issue/Capital Change
2026
Apr 23
Share Issue/Capital Change
2026
Apr 23
Annual Report
2026
Apr 9
Proxy Solicitation & Information Statement
2026
Mar 30